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was definite in 9 and 7 patients and probable in 12 and 7 
patients, respectively. The clinical picture of ReA caused 
by YE biotype 1A was similar with other bio/serotypes of 
YE. The definite ReA due to YE biotype 1A occurred in 
middle-aged adults (5 men, 4 women) with the most fre-
quently affected joints being the knees and ankles. We sug-
gest that YE biotype 1A should be taken into account as a 
new trigger of ReA.
Keywords Infection arthritis · Reactive arthritis · 
Spondyloarthritis · Yersinia enterocolitica
Introduction
Yersinia enterocolitica (YE) is an enteropathogen causing 
foodborne infections. There are six different biotypes of YE 
(biotypes 1A, 1B, 2–5), of which biotypes 1B and 2–5 are 
considered pathogenic, while biotype 1A is generally con-
sidered non-pathogenic [1]. Each biotype can include several 
different serotypes, some of which occur in both biotype 1A 
and pathogenic biotypes [2]. Because biotype 1A has been 
isolated from stools of diarrheic patients, its potential patho-
genicity has been discussed in the literature [2, 3].
In Finland, with a population of 5.4 million, about 600 
cases of yersinosis (mean annual incidence 11.1/100,000) 
have been reported annually in recent years [4]. The 
mean annual incidence of yersinosis was 7.2/100,000 in 
2001–2008 in Germany [5] and 1.2/100,000 in 1998–1999 in 
a survey from Northern America [6]. YE infections usually 
appear sporadically, but some outbreaks have been reported 
[7–9].
Typical clinical symptoms of acute YE infection include 
diarrhea, abdominal pain, and fever, occasionally also vomit-
ing; mesenteric lymphadenitis and terminal ileitis can mimic 
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acute appendicitis. Reactive arthritis (ReA), an inflamma-
tory sterile arthritis, and erythema nodosum can occur after 
YE infection [10–14].
Studies on YE-related ReA have focused on the tradition-
ally pathogenic serotypes O:3 and O:9 [10–12, 15]. Only 
one study found musculoskeletal complications, which the 
authors considered potentially related to YE biotype 1 [11]. 
Furthermore, Huovinen et al. reported recently symptoms 
related to ReA attributable to YE biotype 1A in 3% of study 
subjects [16].
The role of YE biotype 1A in causing reactive musculo-
skeletal complications is unclear. The aim of this clinical 
study was to investigate the clinical picture and severity of 
ReA and other musculoskeletal complications associated 
with gastrointestinal infection caused by YE biotype 1A and 
also compare, if the clinical picture differs from ReA caused 
by traditionally pathogenic YE biotypes.
Patients and methods
Study design
The study was carried out in collaboration with the National 
Institute for Health and Welfare (THL) as part of a case–con-
trol study investigating the clinical features and sources of 
YE infections [16]. The study protocol was approved by the 
Ethics Committees of the Hospital District of Helsinki and 
Uusimaa and THL.
In brief, all Yersinia-positive stool specimens (exclud-
ing Y. pseudotuberculosis) were collected from 10 clinical 
microbiology laboratories, which annually report approxi-
mately two-thirds of all Finnish Yersinia cases. Two hundred 
and ninety-five subjects were included in the aforementioned 
case–control study. They had all answered to a detailed 
questionnaire concerning abdominal and extra-abdominal 
symptoms related to YE infection, including questions on 
the presence and duration of musculoskeletal (painful and 
swollen joints, limitation of joint movement, pain in ten-
don insertions, low back pain, neck pain), urinary (dysuria, 
hematuria) and eye symptoms (redness without discharge, 
pain, photophobia), and uveitis. Also, possible visits to a 
physician or a hospital and the use of antimicrobials in rela-
tion to current YE infection were asked.
Of these 295 subjects, 120 (41%) who reported new mus-
culoskeletal symptoms related to the current YE infection 
were included in the present study. We attempted to con-
tact all these 120 subjects by the telephone for a detailed 
interview and to invite them to a clinical examination by a 
rheumatologist (RT). The phone interview included previous 
history of musculoskeletal diseases, a detailed history of the 
symptoms related to YE infection supplemented by a review 
of the questionnaire and a permission to acquire copies of 
patient files from a local physician or hospital, which were 
thoroughly reviewed. In addition, a detailed examination of 
joints and tendons was an essential part of the clinical exam-
ination. Blood specimen collected from clinically examined 
patients were screened for human leukocyte antigen (HLA)-
B27, rheumatoid factor (RF), C-reactive protein (CRP), and 
erythrocyte sedimentation rate (ESR) (Fig. 1).
Diagnostic criteria
ReA was defined as the development of synovitis (swollen 
joint with pain or with painful movement) in a previously 
asymptomatic joint, or as inflammatory low back pain (low 
back pain that was worse at night) within the first 2 months 
after the gastrointestinal infection [17]. This definition of 
ReA fulfils the preliminary diagnostic criteria presented in 
the 4th international workshop on reactive arthritis in 1999 
[18]. Reactive enthesitis and tendinitis (ReTe) was defined 
as the presence of tendinitis, heel or elbow pain, and limited 
movements of joints without joint swelling related to the 
current infection. Arthralgia (Alg) was defined as pain in 
a previously asymptomatic joint without swelling and with 
a normal range of movement of the joint. The diagnoses of 
ReA, ReTe, and Alg were defined as “definite” when based 
on clinical examination and/or on interview by phone with 
review of copies of patient files from a local physician or 
hospital and “probable” when based solely on the question-
naire. Subjects with previous rheumatologic diagnosis or 
degenerative musculoskeletal problems were excluded.
Statistical analysis
Proportional data were compared with the χ2 test or with 
Fisher’s exact test. The Mann–Whitney U test or Student’s 
t test was applied in comparisons of continuous variables. 
Differences at the 5% level were considered statistically sig-
nificant. Data were analyzed with the SPSS statistical soft-
ware system, version 16.0 (SPSS, Inc., Chicago, IL, USA).
Results
Patients with musculoskeletal symptoms
Of the 120 patients with musculoskeletal symptoms, 
58 patients (48%) were interviewed by telephone and 62 
patients (52%) were not contacted by telephone and their 
data were collected solely from the questionnaire.
Of these 120 patients, 13 patients were excluded, because 
of degenerative musculoskeletal problems, five were 
excluded because of other rheumatic disease (rheumatoid 
arthritis 2, psoriatic arthritis 1, ulcerative colitis-related 
spondyloarthropathy 1, fibromyalgia 1), one was excluded 
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because of Salmonella enteritis 3 months earlier and one was 
excluded because the musculoskeletal symptoms developed 
later than 2 months after the gastrointestinal symptoms.
After the exclusion, the present study comprises 100 
patients. Of these, 51 were clinically examined and/or inter-
viewed by phone and, in the remaining 49, data were based 
merely on the questionnaire. The mean age of these patients 
was 48.4 (range 20–89) years; 61 were females. There were 
no patients under the age of 16.
Of the 100 patients, 68 had YE biotype 1A, 17 had other 
YE bio/serotypes (4/O:3 n = 16, 2/O:9 n = 1), 14 had YE-like 
strain (Y. frederiksenii 7, Y. kristensenii 2, Y. bercovieri 2, 
Y. intermedia 2, Y. mollaretii 1), and 1 had a non-biotypable 
YE strain. The patient with the non-biotypable YE strain was 
analyzed among the biotype 1A group.
As features of YE infection, 82 reported diarrhea, 81 
abdominal pain, and 15 vomiting. Symptoms related to the 
lower urinary tract were reported by 12 patients. Altogether 
41 patients reported eye symptoms. Two patients had uveitis, 
one of them with YE biotype 1A infection and the other with 
Y. frederiksenii infection; both of these patients also had 
ReA. One patient with YE biotype 1A infection reported 
erythema nodosum.
Reactive musculoskeletal symptoms
Of the 100 patients, 84% reported joint pain, low back pain 
was reported by 59%, pain on joint movement by 58%, joint 
swelling by 28%, and 19% reported warmness/redness of the 
joint. Twenty-nine patients (29%) had visited a local doctor 
because of musculoskeletal symptoms.
Of the 100 patients with musculoskeletal symptoms, 21 
(21%) fulfilled the criteria for ReA and an additional 14 
(14%) for ReTe. None of the patients with ReA had ReTe, 
and none of the patients with ReTe had ReA. The diagno-
sis remained arthralgia in 65 patients (65%). Of these 21 
patients with ReA, the diagnosis was definite (confirmed 
with clinical examination and/or telephone interview with 
review of copies of patient files from a local physician or 
hospital) in 9 and probable (based solely on data of the 
questionnaire) in 12 patients. Of the 14 patients with ReTe 
and of the 65 patients of arthralgia, the diagnosis was defi-
nite in 7 and 35 patients and probable in 7 and 30 patients, 
respectively. The distribution of musculoskeletal symptoms 
occurring after infection of different bio/serotypes of YE is 
shown in Table 1. The clinical picture of ReA caused by YE 
biotype 1A was similar with other bio/serotypes of YE (data 
not shown).
Patients with definite YE triggered ReA
The clinical picture of nine patients with definite ReA is 
shown in Table 2. They were all adults (5 men, 4 women) 
with a mean age of 49 (range 27–76) years. The most fre-
quently affected joints were the knees and ankles, followed 
by small joints of the hands, and wrists. Of extra-articular 
features, one patient had uveitis. The clinical picture of defi-
nite ReA did not differ from that of probable ReA (data not 
shown).
Fig. 1  Study flowchart. ReA 
reactive arthritis; YE Yersinia 
enterocolitica. *13 patients 
excluded because of degenera-
tive musculoskeletal problems, 
5 patients excluded because 
of other rheumatic disease, 
one patient excluded because 
Salmonellosis 3 months earlier, 
one patient excluded because 
musculoskeletal symptoms 
developed over 2 months after 
the gastrointestinal symptoms
12 patients with probable ReA9 patients with definite ReA
100 patients included in data analysis 
of the present study
51 patients clinically examined 
and/or interviewed by phone (with 
copies of patient files from a local 
physician or hospital)
49 patients whose data were 
collected solely from the 
questionnaire
295 subjects with YE infection
120 subjects with YE infection who 
reported musculoskeletal symptoms
20 patients excluded* 
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Clinical examination
Of the 100 patients, 14 participated in the clinical examina-
tion. The patients were seen a mean (median) of 30 (30) 
(range 28–34) months after the positive stool samples were 
taken. The musculoskeletal symptoms had mainly resolved 
by the clinical examination. One HLAB27-positive patient 
who had ReA had still tenderness in the sacroiliac joints. 
This patient, who had had Y. frederiksenii in the stool cul-
ture, had also suffered from uveitis in the acute phase of the 
disease.
The prevalence of HLA-B27 was 25% (1 of 4) among 
patients with ReA, 0% (0 of 1) among patients with ReTe, 
and 33% (3 of 9) among patients with arthralgia. None of the 
patients tested were positive for RF, and the mean values for 
CRP and ESR were within normal limits.
Discussion
As far as we know, this is the first study to show that YE 
biotype 1A can trigger ReA. ReA occurred in middle-aged 
subjects and not only affected predominantly the joints of 
the lower extremities (knees, ankles), but also the wrists 
and small joints of the hands. One patient had uveitis and 
one patient suffered from urethritis, both of which are well-
known extra-articular features of ReA [19]. Urethritis as 
an extra-articular manifestation of ReA has been described 
also in cases triggered by gastrointestinal infection, such as 
Yersinia [12] and Salmonella [20]. It is also possible that our 
patient had urethritis due to Chlamydia trachomatis infec-
tion but we could not exclude this because Chlamydia was 
not investigated. One patient also had erythema nodosum, 
a complication typically associated with Yersinia infection 
[21]. Taken together, the clinical characteristics of ReA 
triggered by YE biotype 1A were similar to those of ReA 
caused by other Yersinia bio/serotypes in the present series 
or described in the literature [12, 22–24].
Our series was based on the study by Huovinen et al., 
which reported prevalence of symptoms of ReA in an epide-
miological study [16]. No data on clinical examination was 
reported in that study, but the clinical rheumatological find-
ings are presented for the first time in the current study. Also, 
the diagnosis of probable ReA was defined more broadly 
in the case–control study by Huovinen et al., whereas we 
applied in the present study more strictly diagnostic criteria 
of ReA used previously by us in several studies [17, 25–29].
Previous investigations of YE-related ReA have concen-
trated on the traditionally pathogenic serotypes O:3 and O:9 
[10–12, 15] or the exact Yersinia bio/serotype is not reported 
[30]. Only one previous study from England has described 
musculoskeletal complications potentially related to YE 
biotype 1 [11]. In that study, exacerbations of spinal and 
Table 1  Distribution of definite or probable reactive musculoskeletal 
symptoms in patients (n = 100) after infection of different bio/sero-
types of Yersinia enterocolitica verified by stool culture
Definite, diagnosis confirmed with clinical examination and/or tel-
ephone interview with review of copies of patient files from a local 
physician or hospital
Probable, diagnosis based solely on data of the questionnaire
Values are presented as n (%) or n
Alg arthralgia, ReA reactive arthritis, ReTe reactive enthesitis and 
tendinitis, YE Yersinia enterocolitica
a One patient with non-biotypable YE strain
YE bio/serotype Patient group ReA ReTe Alg
1A Definite 6 (18) 2 (6) 25 (76)
Probablea 10 (28) 4 (11) 22 (61)
2/O:9 Definite 0 0 0
Probable 0 0 1 (100)
4/O:3 Definite 2 (22) 3 (33) 4 (45)
Probable 2 (29) 3 (42) 2 (29)
YE-like strain Definite 1 (11) 2 (22) 6 (67)
Probable 0 0 5 (100)
Total Definite 9 (18) 7 (14) 35 (68)
Probable 12 (25) 7 (14) 30 (61)
All 21 (21) 14 (14) 65 (65)
Table 2  Clinical picture of 9 patients with definite reactive arthritis 
triggered by different Yersinia enterocolitica biotypes
YE Yersinia enterocolitica





Number of patients 6 2 1
Age, years, mean 
(range)




Distribution of affected joints, n (%)
 Shoulder 1 (17) 0 0
 Elbow 2 (33) 0 0
 Wrist 2 (33) 0 0
 Fingers 2 (33) 1 (50) 1 (100)
 Knee 4 (67) 0 0
 Ankle 4 (67) 0 0
 Feet 1 (17) 1 (50) 1 (100)
Low back pain, n 
(%)
2 (33) 1 (50) 1 (100)
Patients with extra-articular features, n (%)
 Uveitis 1 (17) 0 1 (100)
 Urethritis 1 (17) 0 0
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peripheral joint symptoms and a significant rise of ESR were 
seen in patients with pre-existing ankylosing spondylitis, of 
whom YE biotype 1 was isolated in fecal culture. Of note, 
no clinical cases of ReA were presented.
All except one patient had recovered from reactive joint 
complications by the time of the clinical examination. The 
time period between the beginning of the musculoskeletal 
symptoms and the clinical examination was long, but it ena-
bled us to show the outcome of reactive arthritis, which was 
favourable. This is in line with previous reports with ReA 
triggered by Shigella [27] or Campylobacter [17]. According 
to the literature the long-term prognosis of ReA triggered 
by YE infection is also usually good. In a 10-year follow-
up study of patients with YE-induced ReA, 5.9% developed 
chronic peripheral arthritis and 35.3% had inflammatory 
back pain associated with HLAB27-positivity [14]. None 
of our patients with reactive joint symptoms were aged under 
16 years, which is consistent with previous reports, indicat-
ing that ReA is infrequent among children [25, 29, 31].
The pathogenicity of YE is usually associated with bio/
serotypes 2–3/O:9, O:5, and 4/O:3. Also biotype 1B is 
considered highly pathogenic, but it is infrequently found 
in Europe [1]. In addition to the Yersinia virulence factor 
plasmid (pYV), the pathogenic strains have other virulence 
genes (inv, ail, ystA and myfA) [3]. Because the known Yers-
inia virulence factor plasmid (pYV) is missing in YE biotype 
1A, this biotype has been assumed to be avirulent. Of the 
virulence genes of Yersinia enterocolitica strains, YE biotype 
1A carries inv and hreP genes, but not ystA and virF [32]. 
The absence of major virulence determinants, especially 
ail, in YE biotype 1A has been interpreted to indicate that 
biotype 1A strains are non-pathogenic to humans. Recently, 
biotype 1A strains have been shown to have high genetic 
diversity [33], and 2% YE biotype 1A strains have been 
found to be ail positive [34].
For the development of ReA, the triggering infection, e.g. 
Yersinia in the gut, invades the mucosa and persists in the 
host either in the epithelium or within associated lymphoid 
tissues. The microbe is disseminated in the joint, where it 
causes inflammatory response. Yersinia heat shock pro-
tein 60 and 19 kd protein of Yersinia urease induce T cell 
responses in inflamed joint [35, 36]. The patient responds 
with cytokine imbalance with a relative lack of T-helper 
cytokines, which may permit the persistence of the trigger-
ing microbe [37]. While often considered apathogenic, YE 
biotype 1A is capable of adhering to and invading epithelial 
cells and of surviving within macrophages. Human isolates 
of YE biotype 1A are also able to induce secretion of pro-
inflammatory cytokines (IL-6, IL-8 and TNF) from mac-
rophages [38].
The Yersinia adhesin (yadA) has also suggested to play 
a role in the development of ReA. In experimental animal 
studies, yadA positive YE serotype O:8 induced arthritis in 
rat [39]. YadA shares a linear tetrapeptide with HLA-B27, 
and antibodies against synthetic peptide including HLA-B27 
homologue sequences of yadA were observed in one-third 
of patients with HLA-B27 associated diseases [40]. The role 
of yadA in the development of arthritis in our patients in the 
present series has to be rejected, however, as the YE biotype 
1A strains do not have yadA [32], even in the case if the 
strain harbors ail gene [41].
Definitive diagnosis of YE infection as a causative agent 
for ReA is best achieved by a positive culture of the microor-
ganism [42]. Cold enrichment seems to increase the number 
of positive biotype 1A cases. It increased the findings of 
biotype 1A strains by 72% and of 4/O:3 and 2/O:9 strains 
by 25% [43]. While cold enrichment is not frequently used 
for human clinical samples in all countries [34, 43], it is 
particularly useful for ReA cases, when the patient is no 
longer diarrheic and there could be a low concentration of 
causative pathogens in the stool sample. The measurement 
of antibodies against YE in sera is another option for estab-
lishing the causative agent in ReA. Antibodies of IgM class 
appear soon after the onset of infection and persist in the sera 
for 1–3 months. IgG and especially antibodies of IgA class 
may persist for several months to years in sera of patients 
after postinfectious arthritis caused by YE [44]. However, 
the accuracy of associations between serologic findings and 
clinical conclusions is hampered by poor standardization of 
serologic methods [45].
Methodologically, the questionnaire-based approach is 
usually the only relevant method to conduct population-
based studies. Our study group has previously used this 
methodology successfully in several large studies [17, 
25–28]. Furthermore, our results were based not only on 
information from the questionnaire but complemented in 
half of the cases with a telephone interview (with copies of 
patient files from a local physician or hospital) and also with 
a clinical examination. ReA was slightly more diagnosed if 
the analysis was based only on the information reported in 
the questionnaire compared with the interview and clinical 
examination. However, the clinical picture of definite ReA 
did not differ from that of probable ReA.
There are limitations in our study. The proportion of the 
patients taking part to the clinical examination was smaller 
than expected. Also the time-period between the acute infec-
tion and the clinical follow-up was long. It might have been 
interesting to study the IgM, IgG, and IgA class antibodies 
and their persistence in subjects with or without musculo-
skeletal symptoms. Because of the epidemiological setting 
of the study, this was not, however, possible. The presented 
results can be considered preliminary and impose the need 
for further studies.
In conclusion, our study provides new evidence of arthri-
togenicity of YE biotype 1A. We suggest that it should be 
taken into account as a new trigger of ReA, but extensive 
1868 Rheumatol Int (2017) 37:1863–1869
1 3
research is warranted to elucidate our findings in future 
studies.
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